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Abstract
Background: Mobile technologies are increasingly being used to manage chronic diseases, including cancer, with the promise
of improving the efficiency and effectiveness of care. Among the myriad of mobile technologies in health care, we have seen an
explosion of mobile apps. The rapid increase in digital health apps is not paralleled by a similar trend in usage statistics by
clinicians and patients. Little is known about how much and in what ways mobile health (mHealth) apps are used by clinicians
and patients for cancer care, what variables affect their use of mHealth, and what patients’ and clinicians’ expectations of mHealth
apps are.
Objective: This study aimed to describe the patient and clinician population that uses mHealth in cancer care and to provide
recommendations to app developers and regulators to generally increase the use and efficacy of mHealth apps.
Methods: Through a cross-sectional Web-based survey, we explored the current utilization rates of mHealth in cancer care and
factors that explain the differences in utilization by patients and clinicians across the United States and 5 different countries in
Europe. In addition, we conducted an international workshop with more than 100 stakeholders and a roundtable with key
representatives of international organizations of clinicians and patients to solicit feedback on the survey results and develop
insights into mHealth app development practices.
Results: A total of 1033 patients and 1116 clinicians participated in the survey. The proportion of cancer patients using mHealth
(294/1033, 28.46%) was far lower than that of clinicians (859/1116, 76.97%). Accounting for age and salary level, the marginal
probabilities of use at means are still significantly different between the 2 groups and were 69.8% for clinicians and 38.7% for
patients using the propensity score–based regression adjustment with weighting technique. Moreover, our analysis identified a
gap between basic and advanced users, with a prevalent use for activities related to the automation of processes and the interaction
with other individuals and a limited adoption for side-effect management and compliance monitoring in both groups.
Conclusions: mHealth apps can provide access to clinical and economic data that are low cost, easy to access, and personalized.
The benefits can go as far as increasing patients’ chances of overall survival. However, despite its potential, evidence on the
actual use of mobile technologies in cancer care is not promising. If the promise of mHealth is to be fulfilled, clinician and patient
usage rates will need to converge. Ideally, cancer apps should be designed in ways that strengthen the patient-physician relationship,
ease physicians’ workload, be tested for validity and effectiveness, and fit the criteria for reimbursement.
(JMIR Mhealth Uhealth 2019;7(9):e13584)  doi: 10.2196/13584
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Introduction
Background
Many would agree that mobile health (mHealth; the use of
portable devices for medical purposes) holds considerable
promise for improving health care and the quality of life for
people with cancer [1]. With internet access growing worldwide
and well over 70% of people in Europe and the United States
owning smartphones, the potential market for mHealth is very
large and is projected to continue to grow [2].
In 2017, there were 325,000 mHealth (health and fitness and
medical) apps with over 3.7 billion downloads [3], reflecting
over 30% growth compared with 2016. Although the number
of apps for wellness management decreased by 18% from 2015
to 2017, the number for managing health conditions increased
by 48% in the same period [3].
Although the potential benefits of mHealth seem particularly
compelling for managing chronic conditions, where the overall
efficacy largely depends on patient compliance that frequently
occurs outside of the formal health care system, prolonged,
regular, and intensive use still represents a major challenge [4].
Apps specifically developed for chronic disease management
have had some initial success but have so far failed to live up
to their expectations [5-7]. Among specific diseases, the greatest
proportion of apps on the market is for mental health and
behavioral disorders (28%), followed by diabetes (16%) and
cardiovascular disorders (11%) [3]. Although nearly 1 in 6
deaths are due to cancer, which is indeed among the leading
causes of mortality (with an estimated 9.6 million deaths in
2018 and approximately 14 million new cases worldwide every
year, projected to increase up to 22 million within the next two
decades) [8], few of the mHealth apps focus on cancer care
(5%). Not only are mHealth cancer apps relatively few, but the
action put forward thus far has not been steered in the right
direction; the available cancer apps mostly focus on awareness
raising and information provision [9] and appear to be used for
limited purposes in the actual health care process, with a
prevailing focus on self-management activities and the
automation of structured and unstructured processes [10].
Although the improved cancer survival rates and outcomes have
led to considering most cancers as chronic, their treatment is
still accompanied by distressing symptoms and serious toxicities
that affect functioning and quality of life [11]. To address these
issues, mHealth has the potential to track the patient experience
and collect patient-reported outcomes to personalize care, draw
insights, and shorten the cycle from research to clinical
implementation [12].
When patients are able to record their experiences in real time
and combine them with passive data collection from sensors
and mobile devices, this information can inform better care for
each patient and contribute to the growing body of health data
that can be used to draw insights for all patients.
Preliminary research has addressed the interest of cancer patients
in the use of mobile technologies to manage their disease
[13,14], whereas the influence of demographic factors on
predicting the use of Web-based health information resources
and its patterns has been mostly assessed with respect to
electronic health technologies [15-17]. Furthermore, unlike
other medical devices, to which mHealth technologies broadly
belongs, mHealth performance mainly depends on whether both
patients and clinicians are actively involved in its use [18-21].
However, current evidence has not addressed oncologists, and
little is known about what incentivizes their use of mobile
technologies; although oncologists have previously been shown
to be open, in principle, to considering mHealth technology as
part of patient care [22].
Objective
In summary, the interest in the use of mobile apps in cancer
care is increasing, but there is little empirical insight into
stakeholders’ perceptions. Therefore, to gain insight into key
stakeholders’ perceptions of the value that mHealth app use
creates, we distributed 2 surveys targeting 2 populations of
mHealth app stakeholders—randomly selected cancer clinicians
and patients who use internet-enabled mobile devices, such as
smartphones. Through these surveys, we gathered data on the
use of mHealth apps by patients and on how clinicians and
cancer patients perceive the value of mHealth app use. In this
study, we therefore aimed to describe the physician and patient
population that utilizes mHealth in cancer care, the activities
they perform, as well as the reasons for not using it.
Methods
Survey Design and Settings
To investigate the use of mHealth in cancer care by patients and
clinicians and the reasons for its use, we conducted a
cross-sectional, international survey from July 2015 to February
2016. The survey included the European Big 5, that is, France,
Germany, Italy, Spain, and the United Kingdom, as well as the
United States. These countries exhibit some of the highest
smartphone ownership rates and have mobile broadband
penetration rates above 75% [23]. Concurrently, although cancer
is now on the rise in developing countries, the overall
age-standardized cancer rate is still approximately 1.8 times
higher in more developed countries [24]. Thus, the diffusion
and the current performance of a health care innovation device
such as mHealth can suitably be investigated in these countries,
ensuring the ecological validity of the study. The first draft of
the survey was based on existing literature and previous surveys
and experiments on mHealth [25-27]. The survey questions
were finalized by the authors and translated into Spanish,
French, German, and Italian by professional medical editors in
the different languages. To guarantee the accuracy of the
translations, we pilot tested them with a group of clinicians and
patient representatives. A final completeness check was
implemented, and all essential items were made mandatory;
when possible, a nonresponse option such as not applicable was
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provided. In the final version of the survey, we asked clinicians
and patients up to 37 and 32 questions, respectively (some on
the questions were dependent on previous answers).
Study Population
Eligible clinicians included oncologists who used smartphones
and other devices for internet access, although not necessarily
for mHealth. Similarly, eligible patients were those diagnosed
with any kind of cancer who owned a smartphone that could
access the internet. The survey was administered through
qualtricsXM, a US-based company established in 2002 that allows
researchers to conduct surveys in communities that are
traditionally hard to reach. To construct the panel, potential
respondents were recruited through the Web (using specific
keywords) and outlined based on their characteristics, and a
stratified sample was later invited to join the research panel.
In particular, patients were selected based on a population panel
that provides recruitment via Web (Web banners, pay per click,
natural optimization of research, affiliate marketing, email, and
online public relations activities). Oncologists were reached out
drawing on panels that are constructed by telephone recruitment
or via recruitment portals starting from specialized
databases—such as those of scientific communities.
The survey was sent to 1800 oncologists and 1800 cancer
patients consisting of a random sample of panelists stratified
by country and age group. Both clinicians and patients were
invited to participate in the study via email through Qualtrics
and were provided with a link leading to the survey. The main
screen of the online questionnaire provided all respondents with
the aim of the study, the investigator information, and the
expected time length of the survey (approximately 10 min). The
respondents’ right to confidentiality was respected, and consent
to participate in the survey was obtained.
One concern when using online recruitment panels is that
subjects rush through the online questionnaire without properly
reading the provided instructions and questions. To increase
the statistical power and reliability of our dataset, we screened
respondents based on several criteria. First, we included control
questions to detect spammers. Those study participants who
failed to answer the control questions, answered all the questions
in the same way, or filled in boxes with no-sense comments
were excluded from our sample (28 clinicians and 68 patients).
Second, we examined the time subjects took to fill out the
questionnaire (for clinicians, a mean of 6.31 min and for
patients, 6.40 min). Extreme deviations from the average time
to complete the questionnaire were treated as outliers and
excluded from further analysis. Thus, respondents within the
lowest 1% percentile (less than 2.5 min) in terms of total time
till survey completion were excluded. Furthermore, we checked
whether the subjects’ internet protocol (IP) addresses
overlapped. In such cases, duplicate entries from the same IP
address were excluded from our analysis (12
respondents—patients—in total).
Variables
The survey instrument included 4 different domains in both the
clinician and patient versions: (1) sociodemographic variables
(age, sex, education, and salary level), (2) mHealth utilization,
(3) mHealth activities performed, and (4) reasons for not using
mHealth. Both clinicians and patients were asked about their
use of mHealth technologies for the management of cancer.
Users, namely, individuals who owned a smartphone or any
other mobile device and who used it for cancer-related purposes,
were then asked to report for what purposes they used mHealth
by choosing from a list of activities. These activities related to
different degrees of pervasiveness of the technology aimed at
highlighting different user expertise levels, based on a previously
designed framework by Nasi et al [10]. As a result, respondents
were further classified as either basic (ie, those who used
mHealth to schedule appointments, access personal health care
information, or read test results only) or advanced users (ie,
people who used mHealth to monitor treatment side effects and
prevent further events). In contrast, respondents not using
mHealth were asked to identify the reasons that had so far
hindered them from adopting the technology using 5-point Likert
scale items in the following format: 1=I completely disagree,
2=I disagree, 3=I neither disagree nor agree, 4=I agree, and 5=I
completely agree.
Statistical Analysis
Descriptive statistics were used to report respondents’
sociodemographic information and the degree of utilization of
mHealth in managing cancer care. To measure the relation
between specific sociodemographic information and the
likelihood of being mHealth users, 2 possible sources of sample
selection bias need to be addressed. First, as the survey was
administered online, the results are influenced by the general
digital divide in the population. Second, the survey was
completed only by patients and clinicians using mobile
technologies for any purpose, ie, if the respondent could access
the internet but was not a user of mobile technologies (eg,
smartphones or tablets), the survey was concluded, and no
further questions were asked. In the first case, the sample
selection bias is relevant but does not influence our results as
the target population of mHealth technologies does not include
people without basic technological endowments (eg, a computer
with internet access). The second source of bias, instead, is more
relevant because it refers to the population having access to the
Web but whose mobile endowment is low. Ideally, we should
not exclude these respondents as they are a part of the potential
target of mHealth. In our sample, only 21 out of 2170
respondents reported not using mobile technologies for any
given purpose. To account for this potential bias that could still
have a potential effect on our results, we used 2 different
statistical approaches, namely, a propensity score–based
regression adjustment (PSBRA) with weighting and a Heckman
probit selection model (HPSM). For both the propensity score
equation in the PSBRA and the selection equation in the HPSM,
the independent variables were the age group, nationality, and
salary level of the respondent. The choice of using 2 different
procedures was motivated by the necessity of testing the
robustness of the obtained estimations because of the
disproportion between censored and uncensored observations.
Analyses were conducted with STATA software, version 14
(Stata Corp).
JMIR Mhealth Uhealth 2019 | vol. 7 | iss. 9 | e13584 | p. 3https://mhealth.jmir.org/2019/9/e13584/
(page number not for citation purposes)
Tarricone et alJMIR MHEALTH AND UHEALTH
XSL•FO
RenderX
Workshop and Stakeholder Engagement
The main results from the survey were shared with several
stakeholders to solicit input and feedback as well as develop
policy recommendations for an appropriate spread of mobile
technologies. An international workshop was organized in
Milan, Italy, to facilitate interaction with over 100 stakeholders,
including patients, clinicians, app developers, the pharmaceutical
and medical technology industry, telecom industries, experts
in medical communications and health education, payers, and
policymakers.
We announced the international workshop through different
channels: (1) the general way, that is, by using the website and
social networks normally used by our university (Bocconi
University) to promote events and (2) a more specific way, that
is, by compiling a mailing list of all potential stakeholders at
the international and national levels. Participation was free of
charge and travel expenses were covered by participants.
The session was intended to focus on the discussion of the
results arising from the survey. Specifically, 3 main questions
were aimed toward participants: (1) why patients and clinicians
do not use mHealth evenly, (2) what are the main barriers that
have slowed the adoption of mHealth in cancer care, and finally
(3) what is the likely effect of mHealth on clinicians’ activity
and on patients’ quality of life. A member of the research team
facilitated the workshop, ensuring the surfacing of diverse
perspectives and a rich discussion of issues. The feedback from
the workshop was used to develop a set of questions that we
posed to an expert roundtable.
The roundtable consisted of 4 participants who represented 2
leading patient and clinician associations: European Cancer
Patient Coalition and the European School of Oncology in
Europe and Healthwise Organization and the Multinational
Association of Supportive Care in Cancer in the United States.
The discussion was moderated by a member of the research
team. Both the workshop and the roundtable were recorded and
professionally transcribed.
Results
Study Population
Valid responses were obtained from 1116 of the clinicians
surveyed (62.00% response rate) and 1033 of the cancer patients
interviewed (57.39%). The respondents’ characteristics are
summarized in Tables 1 and 2. The patients were mostly female
(637/1033, 61.66%) and aged over 45 years (798/1033, 77.25%),
whereas the clinicians were mostly male (795/1116, 71.24%)
and evenly apportioned between the 2 age groups. With respect
to education, 28.46% of patients (294/1033) had received no
education or had only attended primary school, 37.37%
(386/1033) had either completed secondary school or achieved
an undergraduate degree, and the remaining 34.17% (353/1033)
had completed graduate (18.0%) or postgraduate (16.2%)
education. Approximately one-third (335/1033, 32.43%) of the
patients were employed full time, 12.88% (133/1033) were
employed part time, and about one-third (366/1033, 35.43%)
were retired. Employed patients prevalently earned less than
US $30,000 per year (178/1033, 17.23%) or between US
$30,001 and US $50,000 per year (129/1033, 12.49%). In
contrast, more than half of the clinicians (721/1116, 64.61%)
earned over US $75,000 per year, with relevant observed
differences between Germany, the United Kingdom, and the
United States (62.7%, 70.4%, and 91.1%, respectively) and
Mediterranean countries (30.5% in France, 26.0% in Italy, and
7.7% in Spain).
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Table 1. Patient sample characteristics by country, 2016.
Total
(N=1033)
United States
(n=511)
United Kingdom
(n=111)
Spain
(n=102)
Italy
(n=105)
Germany
(n=101)
France
(n=103)
Patient characteristics
Sex, n (%)
396 (38.33)187 (36.6)53 (47.7)37 (36.3)39 (37.1)45 (44.6)35 (34.0)Male 
637 (61.67)324 (63.4)58 (52.3)65 (63.7)66 (62.9)56 (55.4)68 (66.0)Female 
Age group (years), n (%)
235 (22.75)106 (20.7)13 (11.7)41 (40.2)31 (29.5)24 (23.8)20 (19.4)Under 45 
798 (77.25)405 (79.3)98 (88.3)61 (59.8)74 (70.5)77 (76.2)83 (80.6)Over 45 
Education level, n (%)
288 (27.88)110 (21.5)28 (25.2)8 (7.8)56 (53.3)57 (56.4)29 (28.2)No or primary education 
392 (37.95)262 (51.3)32 (28.8)34 (33.3)8 (7.6)24 (23.8)26 (25.2)Secondary or undergraduate education 
186 (18.01)42 (8.2)30 (27.0)48 (47.1)29 (27.6)7 (6.9)30 (29.1)Graduate 
167 (16.17)97 (19.0)15 (13.5)12 (11.8)12 (11.4)13 (12.9)18 (17.5)Postgraduate 
Employment status, n (%)
335 (32.43)146 (28.6)28 (25.2)57 (55.9)43 (41.0)29 (28.7)32 (31.1)Full-time employed 
133 (12.88)65 (12.7)15 (13.5)5 (4.9)16 (15.2)19 (18.8)13 (12.6)Part-time employed 
54 (5.23)21 (4.1)1 (0.9)15 (14.7)6 (5.7)5 (5.0)6 (5.8)Unemployed 
52 (5.03)26 (5.1)9 (8.1)7 (6.9)1 (1.0)5 (5.0)4 (3.9)Not employed and not looking for work 
83 (8.03)50 (9.8)7 (6.3)4 (3.9)7 (6.7)9 (8.9)6 (5.8)Unable to work 
10 (0.97)6 (1.2)01 (1.0)3 (2.9)00Student 
366 (35.43)197 (38.6)51 (45.9)13 (12.7)29 (27.6)34 (33.7)42 (40.8)Retired 
Salary level, n (%)
178 (17.23)33 (6.5)19 (17.1)42 (41.2)41 (39.0)20 (19.8)23 (22.3)≤US $30,000 
129 (12.49)54 (10.6)14 (12.6)18 (17.6)13 (12.4)14 (13.9)16 (15.5)US $30,001-US $50,000 
78 (7.55)52 (10.2)6 (5.4)04 (3.8)10 (9.9)6 (5.8)US $50,001-US $75,000 
83 (8.03)72 (14.1)4 (3.6)2 (2.0)1 (1.0)4 (4.0)0>US $75,001 
565 (54.70)300 (58.7)68 (61.3)40 (39.2)46 (43.8)53 (52.5)58 (56.3)Missing or not applicable 
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Table 2. Clinician sample characteristics by country, 2016.
Total
(N=1116)
United States
(n=526)
United Kingdom
(n=108)
Spain
(n=104)
Italy
(n=123)
Germany
(n=150)
France
(n=105)
Sample characteristics
Sex, n (%)
795 (71.24)394 (74.9)74 (68.5)55 (52.9)81 (65.9)116 (77.3)75 (71.4)Male 
321 (28.76)132 (25.1)34 (31.5)49 (47.1)42 (34.1)34 (22.7)30 (28.6)Female 
Age group (years), n (%)
577 (51.70)286 (54.4)70 (64.8)66 (63.5)44 (35.8)49 (32.7)62 (59.0)Under 45 
539 (48.30)240 (45.6)38 (35.2)38 (36.5)79 (64.2)101 (67.3)43 (41.0)Over 45 
Education level, n (%)
0000000No or primary education 
0000000Secondary or undergraduate educa-
tion
 
0000000Graduate 
1116 (100.00)526 (100.0)108 (100.0)104 (100.0)123 (100.0)150 (100.0)105 (100.0)Postgraduate 
Employment status, n (%)
1116 (100.00)526 (100.0)108 (100.0)104 (100.0)123 (100.0)150 (100.0)105 (100.0)Full-time employed 
0000000Part-time employed 
0000000Unemployed 
0000000Not employed and not looking for
work
 
0000000Unable to work 
0000000Student 
0000000Retired 
Salary level, n (%)
32 (2.87)5 (1.0)1 (0.9)6 (5.8)13 (10.6)4 (2.7)3 (2.9)≤US $30,000 
144 (12.90)4 (0.8)10 (9.3)48 (46.2)40 (32.5)14 (9.3)28 (26.7)US $30,001-US $50,000 
205 (18.37)31 (5.9)20 (18.5)42 (40.4)37 (30.1)34 (22.7)41 (39.0)US $50,001-US $75,000 
721 (64.61)479 (91.1)76 (70.4)8 (7.7)32 (26.0)94 (62.7)32 (30.5)>US $75,001 
14 (1.25)7 (1.3)1 (0.9)01 (0.8)4 (2.7)1 (1.0)Missing 
Patient and Clinician Usage of Mobile Health
Of the 2149 participants surveyed, 1153 (53.65%) had
previously accessed some sort of mobile technology for
cancer-related purposes. Different mHealth access rates were
observed in the 2 end-user groups. Among patients, 28.46%
(294/1033) were mHealth users: nonusers were the majority in
all countries assessed, although there were between-country
differences. Clinicians, in contrast, were most often mHealth
users: 76.97% of the respondents (859/1116) utilized mobile
technology in their daily activity or in the management of cancer
patients. The highest percentage was observed in the United
States (459/526, 87.26%). Regarding the intensity of use, we
observed that among clinician respondents, 32.26% (360/1116)
were advanced users and 44.71% (499/1116) were basic users,
whereas 18.39% (190/1033) of patients reported being advanced
users versus 10.16% (105/1033) of basic users (Table 3).
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Table 3. Distribution of users and nonusers of mobile health in the analyzed countries, 2016 (N=2149).
TotalUnited StatesUnited KingdomSpainItalyGermanyFranceUsers
N=1033n=511n=111n=102n=105n=101n=103Patients, total
294 (28.46)155 (30.3)18 (16.2)25 (24.5)46 (43.8)34 (33.7)16 (15.5)Users, n (%)
104 (10.07)56 (11.0)6 (5.4)9 (8.8)15 (14.3)10 (9.9)8 (7.8)Basic users
190 (18.39)99 (19.4)12 (10.8)16 (15.7)31 (29.5)24 (23.8)8 (7.8)Advanced users
739 (71.54)356 (69.7)93 (83.8)77 (75.5)59 (56.2)67 (66.3)87 (84.5)Nonusers, n (%)
N=1116n=526n=108n=104n=123n=150n=105Clinicians, total
859 (76.97)459 (87.3)92 (85.2)60 (57.7)72 (58.5)104 (69.3)72 (68.6)Users, n (%)
499 (44.71)301 (57.2)56 (51.9)36 (34.6)35 (28.5)38 (25.3)33 (31.4)Basic users
360 (32.26)158 (30.0)36 (33.3)24 (23.3)37 (30.1)66 (44.0)39 (37.1)Advanced users
257 (23.03)67 (12.7)16 (14.8)44 (42.3)51 (41.5)46 (30.7)33 (31.4)Nonusers, n (%)
Clinicians’ and Patients’ Mobile Health Activities
Among the patients classified as mHealth user, approximately
half of the respondents used mobile technologies for automation
and decision-making support into activities such as scheduling
an appointment (157/294, 53.4%), accessing personal
information (147/294, 50.0%), and reading test results (135/294,
45.9%). Only approximately one-third of users and, therefore,
about one-tenth of total patient respondents, supported treatment
and follow-up phases through mHealth by either monitoring
side effects (108/294, 36.7% of users), helping prevent further
events (85/294, 28.9%), or taking medications as prescribed
(97/294, 33.0%; Table 4). With regard to clinicians, the majority
accessed mHealth to carry out activities that pertain to the
automation and interaction domains: 88.6% (761/859) used
mobile apps to perform literature research, 66.9% (575/859) to
interact with their colleagues, and 44.6% (383/859) to
communicate directly with patients. Fewer clinician users
utilized mHealth for decision-making purposes: 46.1% (396/859)
used mobile apps to access patients’ electronic health records,
44.0% (378/859) to collect test results, and a smaller number
(324/859, 37.7%) of users used mHealth to support decision
making for ordering further tests. A minority of users performed
activities that support treatment and follow-up in the care
process, such as side-effect management (318/859, 37.0%) and
compliance monitoring (116/859, 13.5%; Table 5).
Table 4. Activities performed by patient users, by degree of pervasiveness of the technology.
Frequency of the activity among total
respondents (N=1033), n (%)
Frequency of the activity among
users (n=294), n (%)
Activities performed by patient users
Activities supporting automation and interaction
157 (15.20)157 (53.4)Schedule an appointment with a physician 
Activities supporting decision making processes
147 (14.23)147 (50.0)Access personal health care information 
135 (13.07)135 (45.9)Get test results 
Activities supporting treatment and follow-up
108 (10.45)108 (36.7)Monitor side effects (nausea, vomiting, and diarrhea) 
85 (8.23)85 (28.9)Help prevent further events (cancer progression and recurrence) 
97 (9.39)97 (33.0)Help in taking medications as prescribed 
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Table 5. Activities performed by clinician users, by degree of pervasiveness of technology.
Frequency of the activity among total
respondents (N=1116), n (%)
Frequency of the activity among
users (n=859), n (%)
Activities performed by clinician users
Activities supporting automation and interaction
761 (68.19)761 (88.6)Literature research
383 (34.32)383 (44.6)Communicate directly with patients
575 (51.52)575 (66.9)Interact with colleagues for timely decision-making
Activities supporting decision-making processes
396 (35.48)396 (46.1)Access patients’ electronic health records
378 (33.87)378 (44.0)Get test results
324 (29.03)324 (37.7)Decision support for ordering further tests
Activities supporting treatment and follow-up
116 (10.39)116 (13.5)To monitor compliance (principal treatment)
318 (28.49)318 (37.0)To manage side effects
Professional Mobile Health Divide Between Clinicians
and Patients
Table 6 shows the marginal probabilities of use at means that
were 69.8% for clinicians and 38.7% for patients using the
PSBRA technique (69.5% and 38.7%, respectively, using
HPSM). Other things being equal, clinicians use mHealth more
than patients, thus, highlighting an inefficient activation of the
complementarities between the two main actors involved in the
process of care. Age and salary level influenced mHealth
adoption in both end-user groups. Among clinicians, younger
professionals exhibited an approximately 15 percentage point
higher likelihood of being mHealth users (82.9% vs 64.6% using
PSBRA), while this gap was even wider for patients, verging
on 30 percentage points. Salary level had a similar impact, with
more affluent respondents more likely to be mHealth users than
the less well-off respondents. These variables also explain the
width of the divide between clinicians and patients. With respect
to age, the divide was significantly higher for old respondents
(35.4% using PSBRA) than that for young respondents (24.5%),
whereas in regard to salary level, the divide was lower for
low-income (29.5% using PSBRA) and high-income categories
(23.2%) and significantly higher for medium-income ones
(between 36.4% and 43.7%). Further differences arose when
country-level situations were addressed, with the divide being
as high as nearly 50 percentage points in the United Kingdom
(51.7% using PSBRA).
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Table 6. Marginal probabilities of mobile health use (N=2149).
HPSMd, %PSBRAc, %Statistical approachesa,b
DividePatientsCliniciansDividePatientsClinicians
31.639.671.231.640.271.8Main effect
Age (years)
25.754.28024.558.582.9≤45 
35.430.66635.429.264.6>45 
Salary
2833.361.229.534.263.7≤US $30,000 
35.734.470.136.434.370.6US $30,001-US $50,000 
44.930.275.243.731.975.5US $50,001-US $75,000 
23.150.573.723.250.874>US $75,000 
Country
35.125.560.634.527.562France 
17.44764.416.643.460Germany 
−0.3e55.555.2−0.8e51.450.6Italy 
20.229.349.519.726.346Spain 
48.9287751.723.875.5United Kingdom 
40.541.682.138.546.284.7United States 
aMarginal probabilities at both values of clinician/patient dummy are displayed.
bThe regression used to estimate propensity scores had a pseudo-R-squared value of 0.15 and the goodness-of-fit test showed a Pearson chi-square value
of 19.1. The logit model included the propensity score as covariate and as probability weight.
cPSBRA: propensity score–based regression adjustment with weighting.
dHPSM: Heckman probit selection model.
eNot significant.
Reasons That Hinder Greater Mobile Health Use
Participants who did not belong to the user category were asked
about their concerns regarding mHealth use and answered
5-point Likert scale items (Table 7). On the patient side, the
most diffused concerns pertained to the preference for traditional
means of communication with their doctor (mean 4.26, SD
0.93), the lack of knowledge about the potentials of information
technologies (mean 3.82, SD 1.17), and the doubts about the
reliability and effectiveness of mHealth for medical purposes
(mean 3.03, SD 1.07). For nonuser clinicians, the most
substantial doubts were related to the preference for in-person
visits (mean 4.13, SD 0.91) and the inability of patients to use
smartphones (mean 3.44, SD 0.94).
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Table 7. Barriers for mobile health (mHealth) use rated on a 5-point Likert-type scale by patient and clinician nonusers.
Mean (SD)Participant, barrier
Patient nonusers
2.65 (1.21)I am worried about the protection of the confidentiality of my personal, medical and health information
2.86 (1.06)I do not trust the technical reliability of the software
3.03 (1.07)I think mobile technologies are not effective and reliable for medical purposes
2.65 (1.08)I am not attracted by mHealth because I cannot use the devices properly
4.26 (0.93)I prefer to communicate and meet my doctor in person
3.82 (1.17)I was not aware of this possibility
2.64 (1.23)I cannot afford the costs of mobile devices and connection
Clinician nonusers
2.89 (1.18)I am doubtful about providing mobile type of support because of data security concerns
2.34 (0.95)I do not trust the technical reliability of the software
2.12 (0.97)I am not interested in mHealth because I cannot use the devices properly
3.02 (1.17)I was not aware of this potential use of mobile phones
2.22 (0.96)I think mobile technologies are not effective and reliable for medical purposes
3.44 (0.94)I realized patients are often not able to utilize mobile technologies
4.13 (0.91)I still prefer to communicate and meet my patient in person
2.90 (1.13)I think it would be uncomfortable mixing the face-to-face relationship with my patients with the virtual practice produced by
mHealth
Qualitative Feedback
The large spectrum of stakeholders involved in the workshop
helped identify further key themes. These were the generic
nature of medical apps, the lack of user-friendliness because of
integration into work and life contexts, the poor interaction
interfaces, and the confusion about whether and when medical
apps must be considered medical devices and whether they must
meet evidential requirements or not. During the roundtable, the
experts agreed that current apps are seldom developed with
patients in mind and that, in many cases, the app functionalities
do not meet patients’ expectations and needs. Therefore,
participants agreed that it would be extremely important to
identify the target audience’s wishes or expectations before
designing and developing new apps. In particular, the
participants emphasized that to define the content of apps, it
would be fundamental to understand the characteristics of the
main target population (ie, old/young user, type and stage of
disease, and different familiarity levels with technology), the
language (the simpler the better, avoiding scientific language,
and making the app immediately easy to use), and the layout
(ie, small fonts on a small screen are a barrier for old people).
Discussion
Principal Findings
With the aging of the population and the epidemics of chronic
diseases, the financial sustainability of health care systems
across the globe is at threat and calls for new paradigms where
patients are empowered to stay healthy and/or to self-manage
their conditions and hospitals only serve to treat the acute phases
of diseases and to connect the community and patients’ home
to deliver long-term chronic care. In such a context, mHealth,
leveraging on the increase in mobile smartphone subscribers
(over 4.4 billion in 2017 [28], representing over 2 out of 3 adults
on earth), is emerging as a viable solution to keep patients
informed and empowered, to provide clinicians with timely data
that can improve their capacity to assess patients’ health status,
and to help improve hospitals to reorganize their production
function and management processes to better fit the evolving
needs of the population [29].
Cancer survivors experience differing needs in terms of medical
care, psychosocial support, and practical needs of daily living,
and mHealth apps can provide access to information and health
behavior interventions that are low cost, easy to access, and
personalized to their specific needs [30]. Benefits can go as far
as increasing a patient’s chances of overall survival [31].
However, despite the largely acknowledged potential and the
increase in artifact development, available evidence on the actual
use of mobile technologies in cancer care and cancer supportive
care is still scant. This study found a utilization rate of mHealth
of less than 30% by cancer patients. These results are slightly
higher, although in the same order of magnitude, compared with
those of a cross-sectional survey administered at a University
Hospital in Spain, according to which 20.3% of the surveyed
hematology-oncology patients had a health app [13]. Clinicians,
in contrast, exhibited a more widespread utilization of mHealth
according to our survey results, with over three-quarters of users
among those surveyed.
In any case, not all users accessed mHealth for the same
purposes; our analysis identified a further gap, the one between
basic and advanced users.
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Clinicians tend to use mHealth mainly in isolation, without
mHealth-based interaction with patients. Indeed, clinician users
reported that they access mHealth extensively to perform
activities that support automation and data collection (such as
Interaction with colleagues and Literature research) and less
often to support clinical decision making.
Our survey results are thus consistent with previously published
studies that highlighted a limited focus of mHealth experimental
studies and apps on treatment and follow-up activities in the
oncology field [9,10].
Several barriers still halt wider adoption by both clinicians and
patients, the main one being the preference for in-person
communication and the related concern that mobile technologies
might hinder the relationship of trust. Both nonuser groups
support these apprehensions, and our results are akin to previous
literature results that identified the wish for personal contact
with the treating physician as the main reason for app refusal
in a cancer patient survey [14] as well as the clinician fear that
mHealth might jeopardize the patient-clinician relationship and
increase their workload [29]. However, according to a broader
systematic, narrative review, after adopting mHealth apps,
patients felt empowered and perceived a positive impact on the
relationship with their providers [32].
On a different note, our analysis confirmed that, as is seen for
the use of internet and smartphones in general, age, education,
and income play important roles in explaining the use of
mHealth in cancer care by both clinicians and patients. However,
other things being equal, we found that the use of mHealth
technologies is significantly more common among clinicians
than among patients and that factors such as age, income, and
origin further contribute to modulating the extent of this divide.
This divide might be present because mHealth, such as most
types of health technologies (eg, medical devices), represents
a work instrument for clinicians who, for the sake of improving
their performance, normally are prone to and represent the
natural target for technological innovation [33,34]. However,
consumers do not normally encounter health technologies until
they become patients and, in principle, would not care at all
about them unless they happened to contract a disease or were
prescribed the technology by their doctors. Much is known
about the typical agency relationship that happens between
patients and doctors together with the supplier-induced demand
that makes patients’ consumption of health care services highly
dependent upon doctors’ advice [13,35,36]. Moreover, there is
evidence that the membership in interprofessional alliances and
networks for change is instrumental to facilitate or hinder the
diffusion process of new technologies [37]. Physicians
participate in specific networks for change that place them in a
privileged position in the diffusion of innovations. Until the
sociodemographic evolution alleviates this trend, clinicians
might play decisive roles in spreading mHealth utilization in
cancer care and recruiting more and more patients to adopt it.
In fact, this professional divide represents a barrier to mHealth
effectiveness in cancer treatment. If the promise of mHealth is
to be fulfilled, clinician and patient usage rates will need to
converge. There is merit in incentivizing oncologists to adopt
cancer apps in routine practice to encourage patients to access
mHealth at greater length.
Incentives for Greater Mobile Health Utilization
To enhance clinician use, several different layers can be
approached. The first dimension pertains to artifact design;
ideally, cancer apps would need to be designed in such a way
that would strengthen the patient-clinician relationship, and
they should be tested for validity, accuracy, and self-efficacy
to help clinicians and patients orient themselves in what now
seems to be an app overload [38].
App designers and developers must do more to bring their end
users into the design process. Our findings point to the need for
app developers to leverage toolkits to enable patients and
physicians to more fully engage in the design and development
process, each contributing with their own expertise [39]. This
will enable the cocreation of solutions. In working toward the
development of a sustainable Information Technology system,
it is important to engage the final users, particularly the
clinicians and patients, throughout the different phases from
problem identification to the design and development phase,
aligning the project trajectory to users’ needs and expectations
and providing clinicians with the opportunity for self-reflection
and revisions. Unfortunately, many mHealth apps are designed
without considering the needs of their users in terms of either
patients or clinicians [4]. The literature lacks empirically
validated guidelines or process models on how to design apps
with stakeholders rather than for stakeholders. As a result, a
recent overview of systematic studies by Byambasuren et al
revealed that most mHealth apps are of low quality [40], which
hinders their recommendations by clinicians and their use by
patients. In cancer care only, Brouard et al evaluated 117 apps
for oncological information and treatment monitoring [41] and
found that the validation of those apps was generally poor
(27.4%).
First of all, these results suggest that designers and developers
need to recognize that a one-size-fits-all approach will not work
when it comes to apps dealing with conditions such as cancer.
Specific apps that account for differences in types of patients,
variance in the stage of the disease, and the kind of care one is
receiving, as well as the expertise one has with using mobile
technologies, will have better chances for increasing adoption
and regular usage.
Second, most health apps lack evidence of clinical effectiveness
and do not undergo a formal validation and evaluation process
[42]; the lack of evidence on whether and under what conditions
mHealth delivers on its promise to improve patients’ health
outcomes and the efficiency of the health care process further
contributes to restraining greater utilization [29,43-45]. More
cancer apps need to be tested for their efficacy as, with few
exceptions [31,46,47], the evidence base in support of mHealth
technologies is still lacking [9]. However, given that the overall
performance of mHealth apps is multidimensional, that is, it
can be measured from different perspectives (eg, patients,
caregivers, and clinicians), it is necessary to develop a
methodological framework to include a wider array of benefits
beside clinical outcomes. This is part of the objectives of
Pushing the boundaries of Cost and Outcome Analysis of
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Medical Technologies, a large, 3-year, European Union funded
project whose recommendations on how to assess mHealth apps
are expected in 2020 [48].
Also, the National Institute for Health and Care Excellence in
the United Kingdom has recently started a project aimed at
providing guidance on the assessment of mobile technologies
(ie, Behaviour change: digital and mobile health interventions)
expected to be delivered in 2020 [49].
Third, efficient regulation can help promote the adoption of
mHealth apps. mHealth apps are classified as medical devices
when they are used for diagnosis, prevention, treatment,
monitoring, or alleviation of disease in human beings and for
this reason must respond to high regulatory standards for
demonstrating clinical benefit and safety [50]. Nevertheless,
regulatory systems have rarely been able to catch up with the
exponential launch of mHealth apps in the global market and
have often been equivocal in establishing whether a
software-based technology has to be treated as a medical device.
This resulted in a very poor number of clinical trials that
included digital health technologies, 860 worldwide in 2017
[51] compared with the number of mHealth apps for managing
health conditions in the same period (126,000) [3], which means
that the large majority of mHealth apps have entered the market
without any clinical evidence in support [52]. This might have
reduced clinicians’ and ultimately patients’ confidence in the
reliability and efficacy of the apps. The US Food and Drug
Administration (FDA) [53] and the Directorate for Health and
Consumers of the European Commission [54] have long been
trying to clarify the regulatory standards that digital health
technologies need to meet and what evidential requirements
need to be developed by app manufacturers. Furthermore, the
FDA has led a working group within the International Medical
Device Regulatory Forum aimed at harmonizing the regulatory
framework for software-based technologies across different
jurisdictions [55] and will include in the fiscal year 2019 budget
a Center of Excellence for Digital Health that will aim at
modernizing the regulatory approach to digital health [56].
These efforts are crucial as they would guarantee common rules
to manufacturers that work in a global environment and would
increase the level of trust in end users.
Fourth, data protection must be addressed to increase end users’
confidence in using mHealth apps. Clinicians still do not feel
the full reassurance about the reliability of the data collected
and of the available apps [57]. Data should not only be reliable
but their usability is also particularly critical: the vast amounts
of data potentially available to patients and providers could
easily overwhelm them if not put to best use. The FDA has
published premarket and postmarket guidance that offers
recommendations for the comprehensive management of
medical device cybersecurity risks and continuous improvement
throughout the total product life cycle as well as incentivized
changing marketing and distributed medical devices to reduce
risks [58]. More recently, the General Data Protection
Regulation, a European Union law, aimed at regulating personal
data in the digital world [59]. Although they are too new to be
assessed, we think these efforts go in the right direction of
increasing clinicians’ and consequently patients’ confidence in
using mHealth apps.
Finally, innovative, multidisciplinary home-based models of
care are now available for cancer patients who can be actively
maintained with oral anticancer drugs and have shown
preliminary success in optimally managing adherence during
pilot testings [60-62]. Although the impact of personalized
mHealth apps on adherence and other significant outcomes of
patients on oral anticancer medications is yet to be assessed
[63], appropriate economic incentives and related formulas are
needed to spur their utilization of these devices [20].
In conclusion, like all other medical devices, mHealth uptake
and diffusion largely depend on clinicians’ conviction, but,
differently from some other medical devices (eg, implantable
devices), the effectiveness of mHealth heavily depends upon
patients playing an active role and using it at the same pace as
clinicians.
Study Strengths and Limitations
This is the first survey including a large, international sample
size comparing 6 different countries in North America and
Europe and, even more importantly, covering the two most
important end users of mHealth: patients and clinicians. In fact,
albeit scant, previous research has primarily addressed cancer
patient needs and attitudes toward mobile technologies and not
those of clinicians. Although past estimates exist for other
specializations [64], to our knowledge, this represents the first
evidence of mHealth utilization by clinicians in the cancer field.
Second, this is the first study that combines the survey approach
with a more qualitative method (workshop and roundtable with
key stakeholders) to better interpret and complement the
quantitative evidence emerging from the survey to ultimately
provide concrete recommendations to decision makers.
However, this study suffers from some limitations that should
be considered in subsequent studies. First, the study was based
on a volunteer online access panel and, thus, is not entirely
representative of the reference population as only individuals
who possess some degree of digital competence could be
reached and included. However, we believe that the online tool
contributed to highlighting the smallest divide between clinicians
and patients, which would likely be larger had we not used a
digital tool. Moreover, the investigation in the user groups of
the activities performed by patients and clinicians who use
mHealth was self-reported and not based on actual records of
their practice. Finally, this survey presents the limit of
generalizability; thus, the divide and the models tested are valid
in cancer and cancer supportive care only, and as much as the
results are extremely significant, they might not hold true for
other types of diseases.
Conclusions
The use of mobile apps in health and in cancer care is literally
booming but poor knowledge exists on who is using mHealth,
for what purposes, what kind of apps are used, and what is the
likely future of mHealth in clinical practice. In this study, we
contributed to filling these gaps: our findings highlight 2 types
of digital divides in cancer care—one mediated by
socioeconomic and educational inequalities among patients and
the other by the rift between how doctors and patients are
deploying these technologies. For mHealth to yield its full
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benefits, it will have to integrate these two ends rather than foment the existing divide.
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